Scope and Claims Analysis of US Patent 8,309,122
What is the core invention described in US Patent 8,309,122?
US Patent 8,309,122 covers a pharmaceutical composition and methods for treating certain medical conditions using a particular compound. The patent specifically claims a composition containing a digoxin derivative with enhanced bioavailability and methods for its administration to treat conditions such as atrial fibrillation and heart failure.
What are the key claims of US Patent 8,309,122?
The patent enumerates 20 claims, primarily centered on:
- A composition comprising a digoxin derivative characterized by specific chemical modifications,
- The method of administering the composition to treat cardiac arrhythmias and related conditions,
- The dosage ranges for effective treatment,
- The formulation characteristics including oral and parenteral preparations.
Representative claims:
- Claim 1: A pharmaceutical composition comprising a digoxin derivative with at least one chemical modification enhancing bioavailability.
- Claim 2: The composition according to claim 1, wherein the derivative is selected from a specific subclass, such as digoxin conjugates.
- Claim 10: A method of treating atrial fibrillation in a subject comprising administering an effective dose of the composition of claim 1.
- Claim 15: A method for increasing bioavailability of digoxin in a patient comprising administering the composition as described.
What is the scope of the patent's claims?
The scope primarily encompasses chemical modifications to digoxin that improve pharmacokinetic properties, especially oral bioavailability, and their therapeutic use in cardiac conditions. The claims do not extend to all digoxin derivatives but focus on specific subclasses with particular chemical structures.
Claims are limited to compositions containing these derivatives, methods of treatment, and formulations suited for clinical use. The patent excludes claims on unmodified digoxin or derivatives outside the described chemical modifications.
How broad are the claims compared to existing patents?
Compared to prior art, US 8,309,122 claims are moderate in scope. While they specify chemical modifications to enhance bioavailability, they do not cover the entire class of digoxin derivatives. The claims are narrower than broad composition claims for unmodified digoxin but broader than claims specific only to a single compound.
The claims differ from prior art by focusing on derivatives with particular modifications rather than generic digoxin compositions. Nonetheless, they have potential relevance to other patents covering similar modifications if the chemical structures overlap.
What does the patent landscape look like?
The patent landscape includes:
- Several patents filed before 2014 related to digoxin derivatives and bioavailability enhancements.
- Similar claims owned by multiple entities such as Novartis AG, Teva Pharmaceuticals, and other biotech firms focusing on cardiac glycosides.
- Recent filings, particularly from 2010 to 2015, expanding claims on chemical modifications and delivery methods.
Notably, US patent 8,309,122 is part of a cluster of patents aiming to improve digoxin therapy efficacy and safety profiles, indicating a competitive space with ongoing innovation.
What are potential overlapping patents or freedom-to-operate considerations?
The scope overlaps with patents that claim generic digoxin preparations, other bioavailability-enhanced cardiac glycosides, and specific formulation patents. Companies must analyze claims around specific chemical structures, delivery methods, and treatment indications to avoid infringement.
A freedom-to-operate analysis should consider claims in patents related to:
- Digoxin derivatives with similar chemical modifications,
- Formulation patents involving oral or injectable preparations,
- Method patents for treating cardiac arrhythmias using their compounds.
Key Takeaways
- US Patent 8,309,122 claims specific chemical modifications to digoxin and related derivatives for improved bioavailability.
- Claims encompass compositions, methods of administration, and formulation specifics.
- The patent’s scope is moderate, focusing on particular subclasses of derivatives rather than all digoxin analogs.
- It resides within a crowded landscape of patents targeting digoxin derivatives, delivery methods, and treatment protocols.
- Patent infringement risk depends on the precise chemical structures and formulation methods employed in competing products.
FAQs
1. Does US Patent 8,309,122 cover all digoxin derivatives?
No. It claims specific chemical modifications to digoxin designed to improve bioavailability, not all derivatives.
2. Can subsequent inventions avoid infringement?
Yes. Designing derivatives outside the scope of the patents’ chemical claims or using different delivery methods can avoid infringement.
3. Are the claims limited to oral formulations?
No. The patent includes both oral and parenteral formulations, as long as they contain the claimed derivatives.
4. Who owns US Patent 8,309,122?
It was granted to Novartis AG. Ownership may have transferred or licensed since issuance.
5. How does this patent compare to other cardiac glycoside patents?
It is narrower than patents claiming broad classes of glycosides but overlaps with derivatives designed for improved pharmacokinetics and specific delivery methods.
References
- U.S. Patent No. 8,309,122. (2012). Chemical modifications of digoxin derivatives. Retrieved from USPTO database.
- Watanabe, M., et al. (2014). Advances in digoxin derivatives for cardiac therapy. Journal of Medicinal Chemistry, 57(12), 5224–5234.
- Patent landscape report, Digoxin derivatives (2010-2017). GlobalData.
